Wex Pharmaceuticals Inc. (TSX:WXI), is pleased to announce that it has initiated a Phase IIa double-blind, randomized, cross-over, placebo-controlled trial of Tetrodin(TM) (Wex’s proprietary formulation of Tetrodotoxin-TTX). This study is designed to evaluate the safety and efficacy in decreasing the severity of withdrawal symptoms in 20 opiate-dependent subjects who are receiving methadone in a treatment program. The first group of 10 patients has been recruited and they are now receiving the treatment (tetrodotoxin/placebo). The dosing period is expected to be completed before the end of the year.
